DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Xerostomia Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Xerostomia, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Xerostomia Market
The market size for Xerostomia in the leading markets is expected to increase significantly during the forecast period 2022–2036.
The United States accounted for the highest Xerostomia market size among the 7MM in 2025 compared to EU4 countries, the United Kingdom, and Japan.
According to Huang et al. (2025), a systematic review and meta-analysis involving 2,486 patients with type 2 diabetes across 16 countries reported an overall xerostomia prevalence of 42.5%, highlighting diabetes as a major contributor to xerostomia burden globally.
According to Rughwani et al. (2025), a Swedish study involving 1.39 million adults reported a diagnosed xerostomia prevalence of 0.23%, with nearly 73.1% of cases occurring in women and 41.5% in individuals aged above 71 years.
According to the European Association of Oral Medicine (2022), xerostomia occurs in approximately 17–39% of individuals aged 65 years or older and is more frequently observed in women than men.
Leading Xerostomia companies such as Lubris BioPharma, MeiraGTx, and others are developing innovative therapies aimed at improving salivary gland function and long-term disease management.
Promising Xerostomia pipeline therapies include LBS-020 and AAV-hAQP1, among others.
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/xerostomia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr
Key Factors Driving the Xerostomia Market
Increasing Disease Burden and Aging Population:The growing prevalence of xerostomia among elderly populations, patients with chronic diseases, and individuals undergoing head and neck radiation therapy is significantly contributing to market growth.
Rising Demand for Effective Symptomatic Therapies:Current therapies such as pilocarpine and cevimeline continue to remain widely used for improving salivary secretion and reducing oral discomfort associated with xerostomia.
Growing Focus on Regenerative and Gene-based Therapies:Pharmaceutical companies are increasingly focusing on regenerative salivary gland therapies, gene therapies, stem cell approaches, and radioprotective agents that may offer disease-modifying benefits beyond temporary symptom relief.
Xerostomia Competitive Landscape
Several Xerostomia therapies in development include LBS-020 (Lubris BioPharma) and AAV-hAQP1 (MeiraGTx).
These therapies target diverse mechanisms such as recombinant lubricin-based oral lubrication and aquaporin-1 gene therapy designed to restore salivary gland function and improve saliva production in radiation-induced xerostomia patients.
Discover more about therapies set to grab major Xerostomia market share @ Xerostomia Treatment Landscape
Recent Developments in the Xerostomia Market
In April 2026, MeiraGTx announced presentation of 3-year data from the Phase I AQUAx clinical study evaluating AAV-hAQP1 for Grade 2/3 radiation-induced xerostomia.
AAV-hAQP1 is currently being evaluated in Phase III clinical trials for radiation-induced xerostomia.
Lubris BioPharma continues to advance LBS-020 as a novel recombinant lubricin-based therapy designed to improve oral lubrication and provide longer-lasting symptomatic relief compared to traditional saliva substitutes.
Researchers in the United States are also developing reusable hydrogel reservoir technologies capable of gradually releasing artificial saliva in the oral cavity, potentially providing sustained symptom relief for xerostomia patients.
What is Xerostomia?
Xerostomia is defined as the subjective sensation or complaint of oral dryness. It may result from reduced salivary secretion due to salivary gland dysfunction or may occur despite normal salivary gland activity.
The condition is commonly associated with medications, autoimmune diseases, endocrine disorders, head and neck radiation therapy, chemotherapy, and lifestyle factors. Patients often experience difficulty swallowing, speaking, chewing, altered taste, oral infections, and dental complications that significantly affect quality of life.
Currently approved systemic therapies for xerostomia include pilocarpine (SALAGEN) and cevimeline (EVOXAC), while topical therapies and saliva substitutes remain important supportive treatment options.
Xerostomia Epidemiology Segmentation
The Xerostomia epidemiology section provides insights into the historical and current Xerostomia patient pool and forecasted trends for the leading markets. The Xerostomia market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:
Total Diagnosed Prevalent Cases of Xerostomia
Treatment Eligible Cases of Xerostomia
Age-specific Diagnosed Prevalent Cases of Xerostomia
Gender-specific Diagnosed Prevalent Cases of Xerostomia
Scope of the Xerostomia Market Report
Therapeutic Assessment: Xerostomia current marketed and emerging therapies
Xerostomia Market Dynamics: Key Market Forecast Assumptions and Market Outlook
Key Companies: Lubris BioPharma, MeiraGTx, and others
Key Therapies: LBS-020, AAV-hAQP1, Pilocarpine (SALAGEN), Cevimeline (EVOXAC), and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Xerostomia Market Access and Reimbursement
To know more about Xerostomia companies working in the treatment market, visit @ Xerostomia Clinical Trials and Therapeutic Assessment
Table of Contents
Xerostomia Market Report Introduction
Executive Summary for Xerostomia
SWOT Analysis of Xerostomia
Xerostomia Patient Share (%) Overview at a Glance
Xerostomia Market Overview at a Glance
Xerostomia Background and Overview
Xerostomia Epidemiology and Patient Population
Country-Specific Patient Population of Xerostomia
Xerostomia Current Treatment and Medical Practices
Xerostomia Unmet Needs
Xerostomia Emerging Therapies
Xerostomia Market Outlook
Country-Wise Xerostomia Market Analysis (2022–2036)
Xerostomia Market Access and Reimbursement of Therapies
Xerostomia Market Drivers
Xerostomia Market Barriers
Xerostomia Appendix
Xerostomia Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: https://www.delveinsight.com/consulting/due-diligence-servicesCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
